Instrument Inactif

Gouvernance LA JOLLA PHARM Other OTC

Recherche biotechnologique et médicale

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

22/08/22	La Jolla Pharmaceutical annonce des changements de direction	CI
22/08/22	Innoviva, Inc. (NasdaqGS:INVA) a finalisé l'acquisition de La Jolla Pharmaceutical Company (NasdaqCM:LJPC).	CI

Comité Exécutif: LA JOLLA PHARM

Dirigeant

Fonctions occupéesDepuis

Pavel Raifeld

42 ans

Chief Executive Officer

01/04/2023

Stephen Basso

60 ans

Treasurer

Katherine Dorris

Corporate Secretary

Composition du Conseil d'Administration: LA JOLLA PHARM

Administrateur

ComitésDepuis

Stephen Basso

60 ans

Director/Board Member

Pavel Raifeld

42 ans

Director/Board Member

22/08/2022

Anciens Dirigeants et Administrateurs: LA JOLLA PHARM

Insider

Fonctions occupées

DepuisJusqu'au

Paula Rusu

Corporate Officer/Principal

01/01/2020

01/05/2023

Larry Edwards

Director/Board Member	29/10/2020	22/08/2022
Chief Executive Officer	28/07/2020	01/04/2023
President	28/07/2020	01/04/2023

Stewart Kroll

Corporate Officer/Principal

01/01/2020

01/09/2022

Kevin Tang

Chairman

27/08/2014

22/08/2022

Robert H. Rosen

Director/Board Member	07/07/2014	22/08/2022
Independent Dir/Board Member	07/07/2014	22/08/2022

Laura Douglass

Director/Board Member	14/10/2013	22/08/2022
Independent Dir/Board Member	14/10/2013	22/08/2022

Craig Johnson

Director/Board Member	15/10/2013	22/08/2022
Independent Dir/Board Member	15/10/2013	22/08/2022

David Ramsay

Director/Board Member	11/10/2019	22/08/2022
Independent Dir/Board Member	11/10/2019	22/08/2022

Marianne Zhen

Director/Board Member

22/08/2022

Tony Hodges

Chief Tech/Sci/R&D Officer

12/09/2021

Thomas J. Ouellette

Sales & Marketing

01/01/2020

01/08/2021

Clara Ezed

Corporate Officer/Principal

01/12/2017

01/12/2020

Lakhmir Chawla

Chief Tech/Sci/R&D Officer

01/07/2015

02/10/2020

Darryl Wellinghoff

Corporate Officer/Principal

11/03/2019

30/09/2020

Christopher Galloway

Chief Tech/Sci/R&D Officer

01/08/2018

01/09/2020

Sandra Vedrick

Human Resources Officer	01/03/2014	01/08/2020
Investor Relations Contact	01/03/2014	01/08/2020

Carol Odle

Corporate Officer/Principal

01/01/2020

01/08/2020

Joseph Ninosky

Corporate Officer/Principal

01/06/2020

Michael Hearne

Comptroller/Controller/Auditor	01/06/2020	-
Director of Finance/CFO	01/06/2020	-
Public Communications Contact	01/06/2020	-
Corporate Secretary	-	-

James Rolke

Chief Tech/Sci/R&D Officer

01/02/2012

31/05/2020

Dennis Mulroy

Comptroller/Controller/Auditor	-	31/05/2020
Chief Executive Officer	-	31/05/2020
Director of Finance/CFO	06/04/2015	31/05/2020

Robin Marsden

Corporate Officer/Principal

01/06/2019

01/05/2020

Jennifer Carver

Chief Operating Officer	01/01/2017	23/11/2019
Corporate Officer/Principal	01/02/2014	01/01/2017

George Tidmarsh

Director/Board Member	19/01/2012	23/11/2019
Chief Executive Officer	19/01/2012	23/11/2019
President	19/01/2012	23/11/2019
Corporate Secretary	19/01/2012	23/11/2019

Jeffrey Jensen

Chief Tech/Sci/R&D Officer	01/03/2016	-
Corporate Officer/Principal	-	-

Chester Zygmont

Director of Finance/CFO

01/06/2012

01/01/2016

Inge Bear

Chief Tech/Sci/R&D Officer	01/07/2014	-
Corporate Officer/Principal	-	-

Deirdre Gillespie

Director/Board Member	28/07/2011	19/01/2012
Chief Executive Officer	14/03/2006	19/01/2012
President	14/03/2006	19/01/2012

Robert A. Fildes

Director/Board Member	01/01/1991	28/07/2011
Chairman	28/07/2011	19/01/2012
Independent Dir/Board Member	28/07/2011	19/01/2012

Bertrand C. Liang

Director/Board Member

08/12/2010

19/01/2012

Saiid Zarrabian

Director/Board Member	19/01/2012	-
Chairman	16/10/2013	18/06/2015
Independent Dir/Board Member	19/01/2012	18/06/2015

Gail A. Sloan

Comptroller/Controller/Auditor	27/04/2009	28/07/2011
Director of Finance/CFO	01/01/1996	19/01/2012
Corporate Secretary	01/01/1996	19/01/2012

Stephen M. Martin

Director/Board Member

01/04/2000

02/06/2011

Craig R. Smith

Chairman

01/01/2004

31/12/2010

Frank E. Young

Director/Board Member

14/12/2005

31/12/2010

Thomas H. Adams

Director/Board Member

01/01/1991

03/09/2009

Martin Sutter

Director/Board Member

14/12/2005

03/09/2009

Michael J. B. Tansey

Chief Tech/Sci/R&D Officer

01/01/2006

25/04/2009

Niv Edward Caviar

Director of Finance/CFO

25/04/2009

Josefina T. Elchico

Corporate Officer/Principal

01/10/2004

25/04/2009

Vickie Motte

Human Resources Officer

01/01/2006

02/01/2009

Nader Naini

Director/Board Member

14/12/2005

22/05/2008

Peter Potgieter

Chief Tech/Sci/R&D Officer

01/01/2007

Steven Engle

Chief Executive Officer	01/01/1995	14/03/2006
Chairman	01/01/1997	14/03/2006
Chief Operating Officer	01/01/1993	01/01/1994
President	01/01/1995	01/01/1997

Bruce K. Bennett

Corporate Officer/Principal

01/01/2002

01/01/2006

James Topper

Director/Board Member

14/12/2005

Toni D. Foster

Chief Operating Officer

01/01/2000

01/01/2005

Lawrence E. Bullock

Director of Finance/CFO

01/01/1996

01/02/2003

Andy Tao

Chief Tech/Sci/R&D Officer

01/01/1997

01/01/2003

Lisa Koch-Hulle

General Counsel

13/04/2010

Kenneth R. Heilbrunn

Chief Tech/Sci/R&D Officer

01/01/2002

Luke Seikkula

Corporate Officer/Principal	01/01/2001	-
Chief Operating Officer	01/01/2019	01/03/2019

Bill Welch

Sales & Marketing	01/01/1998	29/06/1999
Sales & Marketing	01/07/2001	01/09/2005

Mark T. Edgar

Corporate Officer/Principal

01/01/1995

01/01/1999

Theodora Reilly

Human Resources Officer

01/01/1998

Matthew D. Linnik

Chief Tech/Sci/R&D Officer

01/01/1998

Paul C. Jenn

Corporate Officer/Principal

01/01/1994

William Ringo

Director/Board Member

01/01/1990

Andrew Wiseman

Public Communications Contact

01/01/1989

Peter G. Ulrich

President

Richard W. Krawiec

Public Communications Contact

Michael J. Walsh

Corporate Officer/Principal

Christopher Wiltshire

Corporate Officer/Principal

Stephen M. Coutts

Chief Tech/Sci/R&D Officer

William E. Engbers

Director/Board Member

Wilmer Leigh Thompson

Director/Board Member

Mark Densel

Corporate Officer/Principal

Daniel Pertschuk

Corporate Officer/Principal

Alejandro Cimadevilla Gonzalez

Corporate Officer/Principal

30/09/2010

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	2
Femme	1

Dont comité exécutif

Homme	2
Femme	1

Dont Administrateurs

Homme	2
Femme	0

La Jolla Pharmaceutical Company s'occupe principalement de la commercialisation de thérapies pour les patients souffrant de maladies potentiellement mortelles. Son portefeuille de produits comprend GIAPREZA (angiotensine II) et XERAVA (éravacycline). Son injection GIAPREZA est un vasoconstricteur indiqué pour augmenter la pression sanguine chez les adultes souffrant de chocs septiques ou autres chocs distributifs. Le GIAPREZA est utilisé pour le traitement de l'hypotension réfractaire chez les adultes atteints de chocs septiques ou autres chocs distributifs. Son XERAVA est un antibactérien de la classe des tétracyclines indiqué pour le traitement des infections intra-abdominales compliquées (IAC) chez les adultes. Ses produits candidats en phase précoce de développement clinique comprennent le TP-6076 et le TP-2846. Le TP-6076 est une formulation IV d'un dérivé entièrement synthétique de la fluorocycline pour le traitement de certaines bactéries gram-négatives multirésistantes. Son TP-2846 est une formulation IV de tétracycline pour le traitement de la leucémie myéloïde aiguë. Son produit candidat comprend également le TP-271.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société